Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stock Watch: Second-Order Pandemic Effects In J&J’s First Quarter

Johnson & Johnson’s First-Quarter 2022 Earnings Report Confounds The Stage Of The Pandemic

Executive Summary

The second-order pandemic effects on labor and logistics that have plagued other sectors appeared across J&J’s earnings announcement. With the biggest impact at its consumer business, why then has demand for J&J’s COVID-19 vaccine plummeted?

You may also be interested in...



Stock Watch: Big Pharma Earnings Season Gets Messy

A post-pandemic rebound in oncology sales contrasts with the lagging revenues of drugs administered by primary care and office-based specialists. Declining COVID-19 vaccine, diagnostic and treatment revenues could add further volatility.

Stock Watch: The Pandemic Cannot Mask Roche’s Weaknesses

Declining COVID-19-related diagnostic and therapeutic sales are likely to expose long-standing weaknesses and amplify the effects of new pressures that were masked during the pandemic.

J&J Continues Signaling Aggressive M&A Approach To Drive Growth

Johnson & Johnson reported disappointing Q1 sales for its COVID-19 vaccine but called the Carvykti launch solid and discussed plans for further diversification of its multiple myeloma portfolio.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC146273

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel